TORONTO and HOUSTON, Nov. 20,
2019 /PRNewswire/ - Medicenna Therapeutics Corp.
("Medicenna" or "the Company") (TSX: MDNA, OTCQB:
MDNAF), a clinical stage Immuno-Oncology company, today announced
that it will host a Key Opinion Leader (KOL) call and webcast for
the investment community on Monday, November
25, 2019 at 10:00 AM,
ET.
The KOL call will focus on Medicenna's MDNA55 recurrent
glioblastoma (rGBM) program and the latest Phase 2b clinical study results which will be presented
by Dr. John Sampson on Sunday, November 24th, 2019 at
the Annual Meeting of the Society of Neuro-Oncology being held
from November 20 to 24 at the JW
Marriott Desert Ridge Resort in Phoenix,
Arizona.
Featured Speaker:
John H. Sampson, MD, PhD,
MHSc, MBA Robert H. and Gloria Wilkins Distinguished Professor and
Chair of Neurosurgery at Duke
University in Durham,
NC
Dr. Sampson is an internationally recognized leader in the field
of brain cancer immunotherapy, experimental treatment of complex
brain tumors and drug delivery to the brain using convection
enhanced delivery (CED). He has authored more than 240
peer-reviewed publications documenting the development of multiple
immunotherapeutic agents that have affected the standard of care in
glioblastoma, the most malignant form of brain cancer. He has
remained continuously funded by the National Institutes of Health
since 2000. Dr. Sampson earned his medical degree from the
University of Manitoba in Winnipeg, Canada and a PhD in neuro-
immunology and brain tumor immunotherapy at Duke University. He completed his MBA at the Fuqua
School of Business. Dr. Sampson was elected to the prestigious
National Academy of Medicine as well as the Association of American
Physicians.
Conference call and webcast details:
Date: November 25, 2019
Time: 10:00 am ET
To access the conference audio:
Local dial in: 416-764-8609
North American Toll Free: 1-888-390-0605
Conference ID No.: 38917905
To access the webcast and slide presentation:
https://event.on24.com/wcc/r/2138171/CE2277E750781D52B6D90A11FFA690DE
Following the event, the archived webcast and Medicenna
presentation will be available on the Company's website
at www.medicenna.com.
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immunotherapy company focused on
oncology and the development and commercialization of novel, highly
selective versions of IL-2, IL-4 and IL-13 Superkines and first in
class Empowered Cytokines™ (ECs) for the treatment of a broad range
of cancers. Supported by a US$14.1M
non-dilutive grant from CPRIT (Cancer Prevention and Research
Institute of Texas), Medicenna's
lead IL4-EC, MDNA55, has completed enrolling patients in a Phase
2b clinical trial for rGBM, the most
common and uniformly fatal form of brain cancer, at top-ranked
brain cancer centres in the US. MDNA55 has been studied in five
clinical trials involving 132 patients, including 112 adults with
rGBM. MDNA55 has demonstrated compelling efficacy and has obtained
Fast-Track and Orphan Drug status from the FDA and FDA/EMA
respectively. For more information, please visit
www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements related to
the Phase 2b clinical trial of MDNA55
for the treatment of rGBM and the future plans and objectives of
the Company, are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ
materially from the Company's expectations include the risks
detailed in the annual information form of the Company dated
June 24, 2019 and in other filings
made by the Company with the applicable securities regulators from
time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information (including, without
limitation, the ability of the Company to fully replicate these
interim data results) may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements only as expressly required by
Canadian securities law.
View original
content:http://www.prnewswire.com/news-releases/medicenna-to-host-key-opinion-leader-call-focused-on-latest-mdna55-recurrent-glioblastoma-phase-2b-clinical-study-results-300961972.html
SOURCE Medicenna Therapeutics Corp.